The future of HIV vaccine research and the role of the Global HIV Vaccine Enterprise
- 1 September 2010
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in HIV and AIDS
- Vol. 5 (5), 414-420
- https://doi.org/10.1097/coh.0b013e32833cfe32
Abstract
This review covers the role of the Global HIV Vaccine Enterprise (the Enterprise), an alliance of independent organizations committed to development of a safe and effective HIV vaccine. It discusses the history, impact on the field, and future directions and initiatives of the alliance in the context of recent progress in HIV vaccine research and development. Significant progress has been made in the field since the release of the 2005 Scientific Strategic Plan (the Plan) of the Enterprise. Over the last year, the Enterprise embarked on an impact assessment of the 2005 Plan and the development of the 2010 Plan. Enterprise Working Groups identified key priorities in the field, several of which are discussed in this review, including changing the nature, purpose and process of clinical trials, increasing and facilitating data sharing, and optimizing existing and mobilizing new resources. This time is an important moment in HIV vaccine research. New clinical trial and laboratory results have created new opportunities to advance the search for an HIV vaccine and reinvigorated the field. The Enterprise will publish its 2010 Plan this year, providing a framework for setting new priorities and directions and encouraging new and existing partners to embark on a shared scientific agenda.Keywords
This publication has 15 references indexed in Scilit:
- Preclinical Studies of a Modified Vaccinia Virus Ankara-Based HIV Candidate Vaccine: Antigen Presentation and Antiviral EffectJournal of Virology, 2010
- Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaquesProceedings of the National Academy of Sciences of the United States of America, 2010
- Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infectionNature, 2010
- Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeysNature Medicine, 2010
- Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in ThailandNew England Journal of Medicine, 2009
- OA06-06 LB. Evidence of vaccine-induced changes in breakthrough HIV-1 strains from the Step trialRetrovirology, 2009
- Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine TargetScience, 2009
- Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeysNature Medicine, 2009
- Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challengeNature Medicine, 2009
- Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infectionProceedings of the National Academy of Sciences of the United States of America, 2008